Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.60 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.60 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CKS1B | P61024 | 2/20 | 0.51 |
| ▸ | SKP1 | P63208 | 2/20 | 0.51 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664453 | 1.00 | SMARCA2 (0.60) | SMARCA2SMARCA4PBRM1ADRA2CGPR119 | |
| SCHEMBL29664457 | 1.00 | SMARCA2 (0.60) | SMARCA2SMARCA4PBRM1ADRA2CGPR119 | |
| SCHEMBL1249642 | 0.89 | SMARCA2 (0.55) | SMARCA2SMARCA4PBRM1GPR119ALDH1A1 | |
| SCHEMBL31152780 | 0.89 | SMARCA2 (0.55) | SMARCA2SMARCA4PBRM1GPR119ALDH1A1 | |
| SCHEMBL4678427 | 0.87 | SMARCA2 (0.57) | SMARCA2SMARCA4PBRM1GPR119ALDH1A1 | |
| SCHEMBL31640089 | 0.86 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1GPR119ALDH1A1 | |
| SCHEMBL4133762 | 0.85 | GPR119 (0.52) | SMARCA2SMARCA4PBRM1GPR119ALDH1A1 | |
| SCHEMBL23368541 | 0.85 | ADRA2C (0.56) | ADRA2CALDH1A1MAPTGAASMN1; SMN2 | |
| SCHEMBL17276765 | 0.85 | CKS1B (0.55) | SMARCA2SMARCA4PBRM1GPR119ALDH1A1 | |
| SCHEMBL14206383 | 0.84 | CYP11B2 (0.55) | SMARCA2SMARCA4PBRM1ADRA2CGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110157251-B | Curing agent composition and coating composition comprising same | ＫＣＣ公司 | 2022-04-01 | — | — | CN | claimed |
| CN-110157251-A | Curing agent composition and coating composition comprising it | ＫＣＣ公司 | 2019-08-23 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| CN-118234726-A | Chimeric compound for androgen receptor protein targeted degradation, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118026997-A | Protein degradation targeting chimeric taking STAT3 as target point, preparation method and medical application thereof | 中国药科大学 | 2024-05-14 | — | — | CN | disclosed |
| EP-4337206-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | Libra Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2023093845-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023093845-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-1998025617-A1 | SUBSTITUTED ARYL PIPERAZINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5563142-A | INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | THE UPJOHN COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0507861-B1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS | UPJOHN CO (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5489593-A | Anti-aids piperazines | THE UPJOHN COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1995017888-A1 | PHENYLMETHYL HEXANAMIDES, AND THE USE THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-06 | — | — | WO | disclosed |
| EP-0507861-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS. | UPJOHN CO (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1991009849-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | SMARCA2 4623/4885SMARCA4 4603/4885PBRM1 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.